Brought to you by 
Gruenenthal licenses Kyorin antibiotic AM-1155
24 May 2013
Executive Summary
Gruenenthal of Stolberg, Germany will hold the exclusive development and marketing rights in Europe, the Middle East, and some Latin American countries to Kyorin Pharmaceutical of Tokyo's AM-1155, a quinolone antibiotic in Phase III in Japan.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gruenenthal licenses Kyorin antibiotic AM-1155
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice